Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulators And Pharma Lock Horns On Pricing In India

Executive Summary

India's drugs price regulator and the pharmaceutical industry appear to be at loggerheads again, after the government indicated that it could consider introducing an "enabling clause" in the existing regulation that would facilitate fixing the prices of around 300 products where market data is not available.

You may also be interested in...



India’s Pricing Tussle Escalates After Regulator Names “Overcharging” Firms

Tensions between India’s apex drug pricing authority and industry appear set to intensify after the regulator flagged up over 600 “suspected” cases of overcharging. The way forward for both sides is probably only through constructive dialogue and a less combative approach. The Pink Sheet delves into the key sticking points around the standoff.

Court Stays Controversial Indian Price Freeze

The Bombay High Court has stayed certain controversial price-related orders by India's National Pharmaceutical Pricing Authority (NPPA), including one pertaining to transitioning "non-scheduled" medicines, as the pharmaceutical industry contests multiple regulatory changes in India.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Topics

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel